Tirzepatide

Tirzepatide is a synthetic 39-amino-acid peptide engineered as the first approved dual agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Like semaglutide, it incorporates a fatty-acid moiety that promotes albumin binding, extending its half-life to support once-weekly dosing. Combined GIP/GLP-1 receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and modulates central appetite pathways; in head-to-head trials, this dual mechanism has produced larger effects on glycemic control and body weight than GLP-1 agonism alone.

Tirzepatide's approval rests on Eli Lilly's SURPASS program (type 2 diabetes) and SURMOUNT program (obesity). SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported mean weight reductions of 16.0%-22.5% across dose levels at 72 weeks in adults with obesity or overweight, versus 2.4% with placebo. SURPASS-2 (Frías et al., NEJM 2021), a head-to-head trial in type 2 diabetes, found tirzepatide produced greater HbA1c reduction and weight loss than semaglutide 1 mg. This evidence supports FDA and EMA approval for glycemic control and chronic weight management.

Educational overview only — no dosing instructions in the public hub.

Gastrointestinal effects (nausea, vomiting, diarrhea, constipation, decreased appetite) are the most frequent adverse events and were reported at similar or somewhat higher rates than with semaglutide in comparative trials. As with other incretin-based therapies, tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies (human relevance unconfirmed; contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2), plus documented risks of acute pancreatitis, gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas, and injection-site reactions. Non-prescription, 'research use only,' or compounded tirzepatide carries additional risks that are harder to bound given the molecule's greater structural complexity relative to single-receptor GLP-1 agonists.

Tirzepatide is a larger, structurally more complex peptide than semaglutide, requiring precise synthesis to maintain the intended balance of GIP and GLP-1 receptor activity. Surging demand and periodic shortages of the approved product have driven a substantial gray market in compounded and 'research-grade' tirzepatide; regulators have issued specific warnings about impurities, incorrect salt forms, and mislabeled concentrations in such products, underscoring why source verification matters more here than for many other peptides.

Approved prescription medication (FDA and EMA) marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), requiring a physician's prescription and medical supervision. Non-prescription, 'research use only,' or compounded tirzepatide products sold outside this regulatory framework are not approved by FDA/EMA for human use, lack quality assurance, and have been the subject of specific regulatory warnings about adverse events linked to compounding errors.